Magazine: Mapping the RNA therapeutics R&D landscape in 2022
In this issue: Mapping research trends with RNA therapeutics and artificial intelligence in drug development for 2022, following the Aduhelm story, tracking drug shortages and more.
Manasi Vaidya
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
Latest articles
All Articles
Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
A close FDA committee vote to authorize molnupiravir indicates that mAbs could still be favored for Covid-19 when available.
By
Astellas, Bayer and Mithra likely to turn up the heat in hot flashes market
Late-stage approaches to treat menopause-related hot flashes are expected to hit the market and may offer safer alternatives
By
Pfizer and Takeda deals put spotlight back on value-based pricing programs
Efforts to pay for a drug based on its value were limited by logistics, but recent deals for cancer…
By
Most of Latin America, Caribbean left behind in Merck’s oral Covid-19 antiviral deal
Many upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
By
Coverage restrictions likely to apply to recently-approved ANCA vasculitis drug
Payers will likely use restrictions seen with other rare diseases when it comes to ChemoCentryx’s recently approved AAV drug.
By
Merck’s molnupiravir: Covid-19 gamechanger status relies on patient risk factors
Molnupiravir access may depend on how risk factors are interpreted but availability could be wider with the help of…
By
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
By
Insurers to squeeze JAK inhibitor access in chronic conditions after FDA safety warning
A recent safety warning added by the FDA to JAK inhibitors approved for inflammatory conditions may mean increased payer…
By